New Protocol: Durvalumab with CARBOplatin and PACLitaxel for Endomterial Cancer

Study

Randomized, double-blind phase III (DUO-E)

Newly diagnosed FIGO Stage III/IV or recurrent endometrial cancer of epithelial histology

Carbo/paclitaxel x 6 => Placebo maintenance (I) vs. Carbo/paclitaxel/durvalumab x 6 => Durvalumab maintenance (II) vs. Carbo/paclitaxel/durvalumab x 6 => Durvalumab + olaparib maintenance

Efficacy

Group I vs. II:

Median PFS: 9.6 mos vs. 10.2 mos (HR: 0.71 [0.57-0.89])

Group I vs. III:

Median PFS: 9.6 mos vs. 15.1 mos(HR: 0.55 [0.43-0.69])

Safety

Grade 3-5 AEs: Neutropenia (23% vs. 22% vs. 27%), anemia (14% vs. 16%. vs. 24%), pneumonitis (0.4% vs. 1.7% vs. 5%)

J Clin Oncol 2023;42(3):283

Westin SN. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

http://doi.org/10.1200/JCO.23.02132

Reviewed by Ulas D. Bayraktar, MD on Jun 21, 2024